Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation

Louis Liu, Esq838 FollowersFollow5ShareSavePlay(9min)CommentsSummaryAquestive Therapeutics received a Complete Response Letter for Anaphylm, focused on usability and packaging, not efficacy or safety.The FDA's required remediation involves packaging modifications, updated instructions, and parallel human factors and pharmacokinetics studies, with no new pivotal clinical trials demanded.AQST's $120 million cash position and manageable burn rate provide sufficient runway to address regulatory feedback and resubmit without immediate liquidity risk.Cautious optimism remains; Anaphylm's commercial path is delayed but fundamentally intact, with upside potential for patient investors willing to tolerate volatility.

Buena Vista Images/DigitalVision via Getty Images The CRL and the Nature of the Deficiencies When I wrote about Aquestive Therapeutics (AQST) on January 12, 2026, the FDA had just informed the company that it had identified “deficiencies thatThis article was written byLouis Liu, Esq838 FollowersFollowI run my own boutique law firm, focusing on investment transactions and disputes. Trained at top U.S. law schools and leading Wall Street law firms, I write here primarily to sharpen my own thinking and to engage with my followers. I endeavor to respond to any substantive comments on my articles. My goal is to identify potential 5–10 baggers at the small- and mid-cap stage through careful fundamental analysis of businesses, financials, and valuations. I focus on early-commercial-stage life sciences companies, insurers, homebuilders, and select consumer-facing businesses. If an article of mine fails to make an intelligent 8th grader understand its thesis, I will skip that opportunity.Analyst’s Disclosure: I/we have a beneficial long position in the shares of AQST either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.